Drugs / APVO-414
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02262910 | Jan 2015 → Dec 2018 | prostate cancer | Aptevo Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-11-06 | Emergent BioSolutions | Results Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer emergentbiosolutions.com ↗ |
| 2013-05-03 | Emergent BioSolutions | Results Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer emergentbiosolutions.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APVO-414 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594540 ↗ |
| Known as | ES414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262910 ↗ |
| Known as | MOR-209 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594540 ↗ |
| Route | Intravenous | “ES414 administered intravenously” NCT02262910 ↗ |